Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK And Valeant Partner On Epilepsy Candidates

This article was originally published in The Pink Sheet Daily

Executive Summary

$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.

You may also be interested in...



Five Positive Opinions From EU's CHMP Brightens Up The New Year

New molecular entities from Valeant/GSK, Eisai, Sanofi and Novartis make the grade for the EU's scientific panel at its January meeting.

Five Positive Opinions From EU's CHMP Brightens Up The New Year

New molecular entities from Valeant/GSK, Eisai, Sanofi and Novartis make the grade for the EU's scientific panel at its January meeting.

Valeant/GSK's Anti-Epileptic Potiga Faces Advisory Committee In Mid-August

High rate of adverse event-related dropouts in clinical trials could be a key focus of panel's discussion of ezogabine, also known as retigabine.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel